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employeAbstract: This 12-week study evaluated the efficacy and safety of capsaicin 8% patch versus pla-
cebo patch in painful diabetic peripheral neuropathy (PDPN). Patients aged 18 years or older with
PDPN were randomized (1:1) to one 30-minute treatment (capsaicin 8% patch or placebo patch) to
painful areas of the feet. Overall, 369 patients were randomized (capsaicin 8% patch, n = 186; placebo
patch, n = 183). Percentage reduction in average daily pain score from baseline to between weeks 2
through 8 (the primary end point) was statistically significant for capsaicin 8% patch versus placebo
(27.4% vs 20.9%; P = .025); improvements in pain were observed from week 2 onward. Versus pla-
cebo, patients treated with capsaicin 8% patch had a shorter median time to treatment response (19
vs 72 days) and modest improvements in sleep interference scores from baseline to between weeks 2
through 8 (P = .030) and weeks 2 through 12 (P = .020). Apart from application site reactions,
treatment-emergent adverse events were similar between groups. No indications of deterioration
in sensory perception of sharp, cold, warm, or vibration stimuli were observed. In patients with
PDPN, capsaicin 8% patch treatment provided modest pain relief and sleep quality improvements
versus a placebo patch, similar in magnitude to other treatments with known efficacy, but without
systemic side effects or sensory deterioration.
Perspective: To our knowledge, this is the first study of the capsaicin 8% patch versus placebo in pa-
tients with PDPN to show that one 30-minute capsaicin treatment provides modest improvements in pain
and sleep quality. Results confirm the clinical utility of the capsaicin 8% patch in the diabetic population.
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Keywords: Capsaicin 8%patch, painful diabetic peripheral neuropathy, NPRS average daily pain score,
Brief Pain Inventory-Diabetic Neuropathy, phase 3 study.October 20, 2015; Revised January 15, March 18, and April 25,
cepted September 29, 2016.
y was funded by Astellas Pharma Europe B.V., Leiden, The
nds. Astellas developed the protocol in conjunction with the
vestigators and provided the study drug. The authors received
support for manuscript preparation from Sarah Reynolds of
Healthcare Communications, London, United Kingdom, and
tance was supported by Astellas Pharma Europe Ltd. The au-
wever, directed and are fully responsible for all content and
decisions for this report.
as consulted for and received research grants from Astellas
Acorda, and Viromed and received speaking honoraria from
N.K. was a paid consultant for Astellas Pharma to support the
f this study and received a research grant from Astellas Pharma.
., and R.J.S. are employed by Astellas Pharma Europe BV. D.S.S. is
d by Chiltern International (CRO) but was exclusively outsourced
to Astellas for the duration of the study. S.K.L. was employed by Astellas
Pharma Europe BV at the time of the study. J.V., J.R.-P., and B.L. have no
conflicts of interest to declare.
Supplementary data accompanying this article are available online at
www.jpain.org and http://www.sciencedirect.com/.
ClinicalTrials.gov registration: NCT01533428.
Address reprint requests to David M. Simpson, MD, Department of
Neurology, Icahn School of Medicine at Mount Sinai, Box 1052, New
York, NY 10029. E-mail: david.simpson@mssm.edu
1526-5900
ª 2016 The Authors. Published by Elsevier Inc. on behalf of the Amer-
ican Pain Society. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
http://dx.doi.org/10.1016/j.jpain.2016.09.008
1
P
Capsaicin 8% Patch in PDPN: The STEP Studyainful diabetic peripheral neuropathy (PDPN) is a
debilitating condition and has been shown to affect
approximately one-quarter of patients with type 2
diabetes mellitus.8 Limited consensus regarding the
optimal management of PDPN has led to variable clinical
management with antidepressants, anticonvulsants, or
opioid medications.22 Each of these therapies act on
the central nervous systemandhave limitations in clinical
practice, including discontinuation because of adverse
events (AEs), lengthy dose titration, drug–drug interac-
tions, the need for frequent, repeat administration,
and the risk of addiction, abuse, and withdrawal symp-
toms.11,21 Furthermore, the results of a systematic
reviewandmeta-analysis of pharmacotherapy for neuro-
pathic pain in adults confirm the modest efficacy of
treatment, and low-moderate tolerability for oral treat-
ments.10
Recent treatment guidance for peripheral neuropathic
pain (PNP) has proposed the capsaicin 8% patch as a
second-line option.10 Capsaicin is a potent, highly selec-
tive vanilloid receptor subtype 1 agonist that causes de-
polarization of the neuron.1 The capsaicin 8% patch
contains 8% weight for weight capsaicin and is opti-
mized for rapid delivery of a high concentration of
capsaicin directly to the skin. This delivery of capsaicin in-
duces defunctionalization of hyperactive nociceptors in
the skin and provides rapid, targeted, and sustained
pain relief after a single treatment.1 Additionally,
minimal systemic absorption limits the potential for
drug–drug interactions, eliminates the need for dose
adjustment in the elderly or patients with renal or hepat-
ic impairment, and minimizes the risk of systemic AEs.2
Phase 3 studies of the capsaicin 8% patch in patients
with postherpetic neuralgia (PHN) and HIV-associated
distal sensory polyneuropathy (HIV-DSPN) showed that
it provided at least 12 weeks of pain relief after a single
application, whereas one trial in HIV-DSPN was nega-
tive.3,6,7,13,19 The ELEVATE study in nondiabetic patients
with PNP reported that the capsaicin 8% patch
provided pain relief noninferior to pregabalin, with a
faster onset of action, fewer systemic side effects, and
greater patient satisfaction with treatment.12 The effi-
cacy and safety of the capsaicin 8% patch in patients
with PDPN has not yet been fully characterized. The pre-
sent study, STEP, is to our knowledge, the first assessment
of the efficacy and safety of the capsaicin 8% patch
versus placebo in this population.
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Study Design and Objectives
STEP was a phase III, randomized, double-blind,
placebo-controlled, multicenter trial performed be-
tween February 2012 and February 2014 and conducted
in the United States (ClinicalTrials.gov Identifier:
NCT01533428). The study was approved by an indepen-
dent ethics committee and was conducted in accordance
with the Declaration of Helsinki and other applicable
guidelines, laws, and regulations. Written informed con-
sent was obtained from all patients.After a 12-day screening period, patients were ran-
domized 1:1 to receive a single treatmentwith the capsa-
icin 8% patch (Qutenza; Acorda Therapeutics, Inc,
Ardsley, NY; obtained from Astellas Pharma Europe BV,
Leiden, The Netherlands) or identical placebo patch to
painful areas of their feet for 30 minutes.
Randomization was coordinated through an interac-
tive voice response system. Patients and study staff
were blinded to treatment assignment but, because the
application of capsaicin 8% patch often results in local-
ized pain and erythema, additional measures were taken
to maintain the study blind: 1) physicians and/or nurses
who conducted clinical assessments and who had access
to, and the responsibility to record, patients’ efficacy
and safety data were separate from those carrying out
the patch application and from thosemeasuring baseline
dermal assessments; 2) results from the dermal assess-
ments at baseline were recorded on paper, sealed in an
envelope and not disclosed to any site staff apart from
the physicians and/or nurses who performed the dermal
assessments; 3) instructions to the patient stressed that
they may or may not experience pain during or after
the application of the patch; 4) all patients were pre-
treated with a eutectic mixture of local anesthetics
(EMLA) containing lidocaine 2.5% and prilocaine 2.5%,
to limit pain or discomfort during the application period;
and 5) the patch application site was covered using
stretchable socks immediately after patch application
and for 24 hours subsequent to removal of the patch to
prevent patient identification of erythema.
The treatment area was mapped at screening and
application visits. Treatment borders were defined by
the painful areas of the feet, up to a total combined sur-
face area of 1,120 cm2 for both feet.
Patients were required to call in daily and report their
average pain over the past 24 hours. The baseline pain
score was defined as the mean score during the 12-day
baseline run-in period, during which patients were
required to have at least 7 valid data entries. After the
capsaicin 8% patch or placebo patch application, pa-
tients visited the clinic at weeks 2, 4, 8, and 12/end of
study (EoS) for assessment.Patients
Eligible patients were aged 18 years or older and had a
diagnosis of PDPN due to type 1 or type 2 diabetes melli-
tus, for $1 year before screening. Further criteria for in-
clusion and key exclusion criteria are presented in
Table 1.Efficacy and Safety Assessments
Primary Efficacy End Point
The primary efficacy end point of the study was the
percentage change in the Numeric Pain Rating Scale
(NPRS) average daily pain score as assessed over the pre-
vious 24 hours according to question 5 of the Brief Pain
Inventory (BPI)-Diabetic Neuropathy (BPI-DN) from base-
line to the mean score over weeks 2 through 8.24
Table 1. Key Inclusion and Exclusion Criteria
KEY INCLUSION CRITERIA KEY EXCLUSION CRITERIA
 HbA1c#11% (96.7 mmol/mol) at 3 to 6 months before screening
and at screening
 <1% difference in HbA1c between screening and prescreening
values
 Patients with HbA1c >11% or >1% difference required rescre-
ening, and could be enrolled if the investigator considered the
HbA1c level was appropriately optimized for that patient
 Stable doses of painmedications for more than 4weeks before the
screening visit. Use of any oral, transdermal, or parenteral opioids,
or topical pain medications including nonsteroidal anti-
inflammatory drugs, menthol, methyl salicylate, local anesthetics,
or capsaicin products on or near the affected areas where study
drug was to be applied, was not permitted. The use of other
medications was permitted, including up to 2 analgesics from
different drug classes (antidepressants and antiepileptics) at fixed
doses
 Minimum of 6 consecutive pain recordings during the screening
period
 Average NPRS score over the last 24 hours of $4 during the
screening period
 Primary pain associated with PDPN in the ankles or above
 Pain that could not be clearly differentiated from, or conditions
that might interfere with, the assessment of PDPN
 Current or previous foot ulcer
 Clinically significant cardiovascular disease within 6months before
screening; significant peripheral vascular disease
 Oral, transdermal, or parenteral opioids, regardless of dose, within
7 days preceding patch application
 Clinically significant foot deformities
 Clinically significant abnormal electrocardiogram at screening
 Any amputation of lower extremity
 Use of any topical pain medication on the painful areas within
7 days preceding patch application or previous treatment with
capsaicin 8% patch or hypersensitivity to capsaicin, capsaicin 8%
patch excipients, EMLA ingredients, or adhesives
 Body mass index $40
 Impaired glucose tolerance only without diabetes mellitus
Simpson et al The Journal of Pain 3The BPI is a widely used and validated numeric rating
scale that measures severity of pain and its interference
with daily function. Each BPI item is scored from 0 (‘no
pain’ or ‘does not interfere’) to 10 (‘pain as bad as you
can imagine’ or ‘completely interferes’) for severity and
interference, respectively. The BPI-DN24 is a version of
the BPI that asks a patient to rate severity and interfer-
ence items specifically for diabetes-related pain, encour-
aging the patient to focus on distal pain associated with
their neuropathy.
Secondary Efficacy End Points
Secondary efficacy end points in this study were: 1)
percentage change in NPRS average daily pain score
(question 5 of the BPI-DN) from baseline to the mean
score over weeks 2 through 12; 2) percentage change
and mean change in average daily pain scores each
week (calculated over weekly windows from week 1
[average of days 1–7] throughout the study to week
12 [average of Days 77–84]); 3) occurrence of $30%
and $50% decrease in average daily pain score from
baseline compared with the mean score over weeks 2
through 8 and 2 through 12 (responder analyses); 4)
percentage change in sleep interference NPRS score
(question 9F of the BPI-DN) from baseline compared
with the mean score over weeks 2 through 8 and 2
through 12; 5) percentage change in sleep interference
according to the NPRS score each week; 6) time to
treatment response, defined as the first of 3 consecu-
tive days on which the patient reported $30%
decrease in average daily pain score from baseline; 7)
overall patient status using Patient Global Impression
of Change at weeks 2, 8, and 12; 8) treatment satisfac-
tion using the Self-Assessment of Treatment II ques-
tionnaire at baseline, weeks 8 and 12; and 9) change
in EuroQol in 5 Dimensions from baseline to weeks 2,
8, and 12.Subgroup Analyses of Primary Efficacy
Variable
Prespecified subgroup analyses of the primary efficacy
variable were performed on baseline average daily pain
score (<7, $7), glycated hemoglobin of A1c (HbA1c;
<6.5%, $6.5%), and duration of PDPN (<3 years, $3 to
<10 years, $10 years). Subgroup analyses were also per-
formed on maximum Neuropathic Pain Symptom Inven-
tory (NPSI)5 dimensions performed at the baseline and
EoS visit; patients were allocated to 1 of 5 dimensions
of the NPSI (evoked pain, pressing subcutaneous pain,
paroxysmal pain, paresthesia/dysesthesia, burning [su-
perficial] spontaneous pain) according to their highest
dimension score.
Safety and Tolerability Assessments
Assessments of the safety and tolerability of capsaicin
8% patch included: 1) treatment-emergent AEs (TEAEs)
and serious AEs; 2) vital signs; 3) laboratory analyses; 4)
dermal assessments (before application of topical anes-
thetic, within 15 and at 60 minutes after patch removal);
5) ‘pain now’ NPRS scores before and after patch applica-
tion; 6) rescue pain medication use on days 1 through 5;
and 7) ‘bedside’ sensory and reflex testing on feet at base-
line and EoS to identify any clinically relevant deficits in
sensory function. Sensory testing was performed as fol-
lows: warm, cold, and sharp assessments were rated as
‘absent,’ ‘diminished,’ ‘normal,’ or ‘painful’ at 3 points
on the dorsal surface (dorsal surface of great toe,
midpoint, and medial malleolus) and 2 points on the
plantar surface (ball andmidpoint) of both feet. Vibration
assessment on the dorsal surface of the great toe was
rated as ‘absent,’ ‘markedly diminished,’ ‘mild loss,’ or
‘normal’ sensation. Achilles tendon reflex assessment
was rated as ‘absent,’ ‘diminished,’ ‘normal,’ ‘hyperac-
tive,’ or ‘clonus.’ The sensory and reflex testing categories
4 The Journal of Pain Capsaicin 8% Patch in PDPN: The STEP Studyreported at baseline and EoS were recorded for each pa-
tient and a category shift schemawas developed to ascer-
tain if patients improved, stayed the same, or worsened in
sensory or reflex function during the study (Fig 1).Statistical Methods
To provide 90% power to detect a 12% difference in
‘average daily pain’ NPRS score (average at baseline vs
average between weeks 2–8), a sample size of 320 pa-
tients (160 per treatment group) was planned. Average
daily pain score and sleep interference were analyzed us-
ing an analysis of covariance model, which included
treatment, gender, and pain score at baseline, HbA1c
at screening, and study site as factors/covariates. In addi-
tion, a repeated measures analysis of covariance model
was used for inferential analyses, which included treat-
ment, study week, Treatment  Week interaction,
gender, pain score at baseline, HbA1c at screening, and
study site as factors/covariates. Regarding imputation, a
baseline or last observation carried forward approach
was used as the primary method, and also in instances
in which a patient left the trial early but had an observa-
tion after day 8. For missing data on days 1 through 7 or
day 8 and $1 more consecutive day(s), the baseline
observation carried forward (BOCF) approach was used.
For day 9 and any day thereafter, the last observation car-
ried forward was imputed. If all post-treatment scores
were missing (including day 1), BOCF was used. To assessA
B
Figure 1. Category shift schema used to judge whether patients im
tion from baseline to EoS. (A) Sharp, warm, cold, and reflex testing;the effect of the baseline or last observation carried for-
ward missing data imputation method, sensitivity ana-
lyses were performed using the BOCF approach to
impute any missing post-treatment daily score for which
a patient left the trial early with missing postbaseline
values. All statistical comparisons were made using 2-
sided tests at the 5% significance level and all confidence
intervals (CIs) were calculated with a 2-sided 95% confi-
dence level, unless specifically stated otherwise. Median
time to treatment effect for each treatment group was
estimated using the Kaplan–Meier method. Overall, no
adjustments for multiple comparisons were performed
for reported P values.
The intention to treat (ITT) population included all
randomized patients who received capsaicin 8% patch
or placebo patch application, and was the primary data
set for efficacy analysis. The per-protocol set (PPS) was
comprised of a subset of patients from the ITT popula-
tion. Exclusion criteria from the PPS included: patch
application <24 minutes (<80% of planned duration) or
>37minutes (>125%of planned duration); no valid mea-
surements of the primary efficacy variable between
weeks 2 through 8; use/change in dose of prohibited/
restricted concomitant medication; nonadherence to in-
clusion or exclusion criteria; and patch application to 1
foot only. The safety analysis set included all patients
who received the study patch application. All results pre-
sented are for the ITT population; unless otherwise spec-
ified, results from the PPS analysis supported those forproved, stayed the same, or worsened in sensory or reflex func-
(B) vibration testing.
Table 2. Baseline Characteristics (Safety
Analysis Set)
Simpson et al The Journal of Pain 5the ITT population. All safety analyses were performed
on the safety analysis set.PARAMETER
CAPSAICIN 8%
PATCH
(N = 186)
PLACEBO
PATCH
(N = 183)
Sex, n (%)
Male 114 (61.3) 101 (55.2)
Female 72 (38.7) 82 (44.8)
Ethnicity, n (%)
Caucasian 132 (71.0) 131 (71.6)
African American 36 (19.4) 38 (20.8)
Asian 4 (2.2) 4 (2.2)
Other 14 (7.5) 10 (5.4)
Mean age [SD], y 63.9 [10.6] 62.0 [10.8]
Mean body mass index [SD] 32.2 [4.5] 31.6 [5.0]
Mean duration of PDPN [SD], y 5.8 [4.0] 5.7 [4.0]
HbA1c at screening
Mean % [SD]* 7.4 [1.3] 7.2 [1.2]
<6.5% (<47.5 mmol/mol),
n (%)
49 [26.3] 57 [31.1]
$6.5% ($47.5 mmol/mol),
n (%)
137 [73.7] 126 [68.9]
Baseline average daily pain* 6.6 (1.4) 6.4 (1.5)
Pain medications before
baseline, n (%)
125 (67.2) 132 (72.1)
Analgesic agentsy 90 (48.4) 101 (55.2)
Anti-epileptic drugs 71 (38.2) 82 (44.8)
Anti-inflammatory/
antirheumatic products
46 (24.7) 41 (22.4)
Topical joint/muscular pain
products
46 (24.7) 45 (24.6)
*Data for ITT population.
yAnalgesic agents were categorized according to analgesics, anilides, natural
opium alkaloids, other analgesics and antipyretics, other opioids, and salicylicResults
Patient Disposition
Of the 761 patients screened, 369 patients were ran-
domized at 29 centers in the United States (186 to capsa-
icin 8% patch; 183 to placebo patch; Fig 2). The single
most common reason for screening failure was the strin-
gent criterion set for stability of glycemic control (HbA1c
#11% [96.7 mmol/mol] at 3–6 months before screening
and at screening, with <1% difference between
screening and prescreening values). All patients who
were randomized (the ITT population) received treat-
ment. A total of 17 patients discontinued from the study
after treatment was initiated. In the capsaicin 8% patch
group, 9 patients discontinued; 7 chose to withdraw
from the study and 2 were lost to follow-up. In the pla-
cebo patch group, 8 patients discontinued; 6 chose to
withdraw from the study, 1 was lost to follow-up and 1
discontinued because of a TEAE. In the capsaicin and pla-
cebo groups, the mean (SD) number of patches used was
2.7 (1.1) and 2.7 (1.1), respectively, with a mean applica-
tion duration of 30.3 minutes (1.4) and 30.4 minutes
(1.7), respectively. Most patients were Caucasian
(71.3%) and baseline characteristics such as age, body
mass index, HbA1c, average daily pain, and duration of
PDPN were similar in both treatment groups (Table 2).
The percentage of patients taking pain medication dur-
ing the study was 76.3% in the capsaicin 8%patch group
and 71.6% in the placebo patch group (Table 3).acid and derivatives.Efficacy
Average Daily Pain
There was a modest and statistically significant reduc-
tion in average daily pain from baseline to between
weeks 2 through 8 in the capsaicin 8% patch group
versus placebo patch (mean [SD] = 27.4% [26.79%] vs
20.9% [28.92%], respectively; P = .025; Fig 3A). Analysis
of change in average daily pain score from baseline to
between weeks 2 through 12 showed that this reductionFigure 2. Patient flow.in average daily painwasmaintained (28.0% [27.3%] vs
21.0% [29.4%], respectively; P = .018; Fig 3B). Absolute
average (SD) daily pain scores at baseline, baseline to be-
tween weeks 2 through 8, and baseline to between
weeks 2 through 12 were 6.6 (1.4), 4.9 (2.2), and 4.8
(2.2) in the capsaicin 8% patch group, respectively, and
6.4 (1.5), 5.0 (2.2), and 5.0 (2.2) in the placebo patch
group, respectively. Results for the sensitivity analyses
were consistent with the primary analysis.
With regard to pain response throughout the study, a
greater numerical percentage reduction frombaseline in
average daily pain score each week became apparent
from week 2 in the capsaicin 8% patch group compared
with the placebo group (Fig 4).
Responder Analyses
Whereas a similar proportion of patients in both groups
achieved at least a 30% reduction in average daily pain
score frombaseline to betweenweeks 2 through 8 (capsa-
icin 8% patch, 39.8%; placebo, 32.8%; P = .108), analysis
of between weeks 2 through 12 indicated that more pa-
tients were responders in the capsaicin 8% patch group
during this period (40.9% vs 31.7%, respectively;
P = .050; Fig 5). Similar proportions of patients in both
groups achieved at least a 50% reduction in average daily
pain score from baseline to weeks 2 through 8 (21.0% vs
Table 3. Pain Medication During the Study
(Safety Analysis Set)
PAIN MEDICATION
CAPSAICIN 8%
PATCH
(N = 186)
PLACEBO
PATCH
(N = 183)
Overall, n (%) 142 (76.3) 131 (71.6)
Category, n (%)
Analgesic agents* 107 (57.5) 105 (57.4)
Antiepileptic drugs 72 (38.7) 82 (44.8)
Anti-inflammatory/
antirheumatic products
57 (30.6) 40 (21.9)
Topical joint/muscular pain
products
56 (30.1) 43 (23.5)
Drug, n (%)
Acetylsalicylic acid 79 (42.5) 75 (41.0)
Gabapentin 58 (31.2) 71 (38.8)
Ibuprofen 30 (16.1) 23 (12.6)
Naproxen 21 (11.3) 15 (8.2)
Pregabalin 14 (7.5) 14 (7.7)
Cyanocobalamin 10 (5.4) 10 (5.5)
Duloxetine 6 (3.2) 9 (4.9)
*Analgesic agents were categorized according to analgesics, anilides, natural
opium alkaloids, other analgesics and antipyretics, other opioids, and salicylic
acid and derivatives.
6 The Journal of Pain Capsaicin 8% Patch in PDPN: The STEP Study18.0%, respectively; P = .403) and weeks 2 through 12
(22.0% vs 19.1%, respectively; P = .446).
Time to Treatment Response
The median time to treatment response was shorter
with the capsaicin 8% patch versus placebo patch, with
50% of patients achieving at least a 30% reduction in
average daily pain after 19 days (95% CI for median,
12.0–37.0) in the capsaicin 8% patch group versus
72 days (95% CI for median, 19.0–not calculable) in the
placebo group (Fig 6).A
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Figure 3. Meanpercentage change in averagedaily pain frombasel
(baseline or last observation carried forward; ITT). Between group dSleep Interference
A greater mean percentage reduction in BPI-DN sleep
interference NPRS score was seen in the capsaicin 8%
patch group versus the placebo patch group from base-
line to between weeks 2 through 8 and weeks 2 through
12 (P = .030 for weeks 2–8; P = .020 for weeks 2–12;
Fig 7A); this was maintained throughout the study with
a greater numerical percentage reduction in sleep inter-
ference observed in the capsaicin 8% patch group
compared with the placebo group from week 2 (Fig 7B).
Additional Efficacy Analyses and End Points
Subgroup analyses of the primary end point using
baseline pain score, HbA1c, and duration of PDPN
(<3 years and$3 to <10 years only) supported the results
for the primary end point within the overall population;
however, analysis using maximum NPSI dimension re-
sulted in mixed observations (Supplementary Fig 1). Of
note, patients whose primary pain type on the NPSI
was ‘paroxysmal pain’ showed the largest numerical
treatment response to capsaicin 8% patch compared
with placebo (estimated mean difference = 13.8%;
95% CI, 29.8% to 2.1%). Numerically more patients in
the capsaicin 8% patch group reported being ‘‘very
much improved’’ or ‘‘much improved’’ in Patient Global
Impression of Change status compared with placebo at
week 8 (39.4% vs 30.2%; P = .075) and week 12 (40.5%
vs 29.7%; P = .169). There were no notable differences
observed at any time point for the change from baseline
in EuroQol in 5 Dimensions total score. At week 12, there
was an association between treatment and outcome fa-
voring capsaicin 8% patch for 2 questions on the Self-
Assessment of Treatment II: ‘‘Over the past 7 days, how
much has the study treatment improved your pain
level?’’ (P = .026, no adjustment for multipleB
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%
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%
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P = .018
ine to between (A)weeks 2 through8 and (B)weeks 2 through12
ifferences were estimated using the least squares method.
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12.3 to -.8; P = .025)
Figure 4. Mean percentage change from baseline in average daily pain score throughout the study (ITT).
Simpson et al The Journal of Pain 7comparisons) and ‘‘Over the past 7 days, how much has
the study treatment improved the following aspects of
your life: mood, temperament, or outlook on life?’’
(P = .015, no adjustment for multiple comparisons).P P 
,
= 
to to,
 = 
,
Figure 5. Proportion of patients who achieved a $30% reduc-
tion in average pain score from baseline to between weeks 2
through 8 and weeks 2 through 12 (baseline or last observation
carried forward; ITT).Safety and Tolerability
Adverse Events
In the capsaicin 8% patch group, 46.8% of patients re-
ported TEAEs comparedwith 33.9%of patients in the pla-
cebo patch group (Table 4). This difference was largely
because of application site TEAEs; 33.9% of patients in
the capsaicin group and 8.2% in the placebo group re-
ported any application site reactions, the most frequent
being application site pain. The percentage of patients re-
porting TEAEs peaked on day 2, plateaued by day 6, and
only 1 patient reported a serious TEAE that was unrelated
to treatment after day 13. One patient in the placebo
group discontinued from the study because of a TEAE (hy-
pertension), which was not considered drug-related. The
proportion of patients with drug-related TEAEs was
higher in the capsaicin 8%patch group (34.9%) compared
with the placebo group (12.6%). Most were mild to mod-
erate in severity; only 3 patients (all in the capsaicin 8%
patch group) had severe drug-related TEAEs (severe
burning sensation [n = 2] and severe application site pain
[n = 1]). No discontinuations because of drug-related
,Figure 6. Kaplan–Meier curves for median time to treatment
response ($30% reduction in average daily pain; safety analysis
set).
8 The Journal of Pain Capsaicin 8% Patch in PDPN: The STEP StudyTEAEsoccurred ineithergroup.Theproportionofpatients
reporting serious TEAEs was low in both groups, and no
drug-related serious TEAEs were reported. No deaths
were reported in this study.
Sensory Perception and Reflex Testing
Assessment of changes in sensory perception and re-
flex testing at EoS versus baseline found that most pa-
tients either had no change (52.5% to 83.8% across
tests) or improved (12% to 30% across tests) in the capsa-
icin and placebo groups (Fig 8A; Supplementary Fig 2).
Overall, worsened sensation was reported by a lower
proportion of patients (4.5% to 21.2% across tests) and
a numerically similar proportion in both groups at EoS
compared with baseline (Fig 8A; Supplementary Fig 2).
The reporting of ‘absent’ sensation decreased for all tests
except cold at the ball of the foot in the capsaicin 8%
patch group, and for all tests in the placebo patch group.
In the capsaicin 8%patch group, patients reporting ‘mild
loss’ vibration sensation increased by 7.9%, and reports
of ‘diminished’ and ‘absent’ vibration reduced by 2.8%
and 4.5%, respectively (Fig 8B). In addition, by EoS, the
proportion of patients reporting ‘normal’ sensation
had increased and the proportion reporting ‘painful’
sensation had reduced for most tests in both groups
(Fig 8C).
Other Safety Findings
Assessment of systolic/diastolic blood pressure and
pulse from before to after patch application found that
a higher proportion of patients in the capsaicin 8%patch
group had a clinically relevant (an increase or decrease of
$20 mm Hg) increase in systolic blood pressure
compared with placebo (8.6% vs 2.7%, respectively); no
clinically significant abnormal electrocardiograms were
recorded.
For dermal assessments, the proportion of patients
with no evidence of irritation was similar in both groups
at baseline (capsaicin 8% patch, 91.4%; placebo patch,94.5%) and at EoS (capsaicin, 95.0%; placebo, 97.2%).
The mean change in ‘pain now’ NPRS scores was similar
in both groups from before EMLA application to within
15 minutes after patch application (1.6 and 2.0 for
capsaicin and placebo, respectively) and from before
EMLA application to within 60minutes after patch appli-
cation (1.8 and 2.2 for capsaicin and placebo, respec-
tively). More patients in the capsaicin 8% patch group
used rescue pain medication for pain caused by patch
application compared with those in the placebo patch
group (18.8% vs 5.5%, respectively), with the anilides
chemical subgroup (eg, acetaminophen) the most
commonly used (10.8% vs 4.9%, respectively).Discussion
In patients with PDPN, a single capsaicin 8% patch
treatment provided modest improvements in pain relief
compared with a placebo patch over a period of
12 weeks. These findings are of similar magnitude to
the effects of other treatments with known efficacy in
neuropathic pain. With regard to secondary end points,
a higher proportion of patients achieved at least a 30%
reduction in average daily pain score from baseline to
between weeks 2 through 12 with capsaicin 8% patch
vs placebo, and the median time to treatment response
was substantially shorter with the capsaicin 8% patch.
The modest improvements in sleep quality observed
with the capsaicin 8% patch were an important finding
of this study, because PDPN is often associated with sleep
disturbance.23 Furthermore, sensory testing found no ev-
idence of deterioration in sensation with capsaicin 8%
patch treatment and most patients reported the same
or improved sensation by EoS. These changes were pre-
dominantly in patients who transitioned from the rating
categories of ‘absent’ to ‘diminished’ or to ‘normal’
sensation during the study, and these interesting find-
ings have been further evaluated in a long-term study.22
No new safety issues were observed in this study,
which, to our knowledge, is the first double-blind study
of the capsaicin 8% patch in patients with diabetes.
Capsaicin 8% patch treatment in patients with PDPN
was most commonly associated with transient applica-
tion site reactions, consistent with observations in
previous studies involving patients with PHN and
HIV-DSPN.3,6,13,19 There were no discontinuations
because of drug-related TEAEs, and no serious TEAEs
that were considered to be drug-related. Taken overall,
the results of this pivotal study, in a group of patients
who are often difficult to treat, extends the range of
PNP etiologies for which the capsaicin 8% patch has
shown efficacy and safety, and led to regulatory
approval in patients with diabetes in Europe.2
The primary end point in this study—percentage
change in average daily pain from baseline to between
weeks 2 through 8—has not been used in previous
studies in PDPN, which commonly measured the differ-
ence in average pain score at specific time points.16,17
Measuring the primary end point over a prolonged
period of time enables assessment of patients’
longitudinal experience rather than providing a
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Figure 7. (A)Mean percentage change in sleep interference score frombaseline to betweenweeks 2 through 8 andweeks 2 through
12 (ITT). Between group differences were estimated using the least squares method. (B) Mean percentage change from baseline in
sleep interference score throughout the study (ITT).
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Table 4. Summary of TEAEs and Drug-Related
TEAEs (Safety Analysis Set)
EVENT, N (%)
CAPSAICIN 8%
PATCH
(N = 186)
PLACEBO
PATCH
(N = 183)
TEAEs 87 (46.8) 62 (33.9)
Most commonly reported TEAEs (>3.0% patients in overall
study population)
Burning sensation 26 (14.0) 5 (2.7)
Pain in extremity 20 (10.8) 10 (5.5)
Application site pain 18 (9.7) 4 (2.2)
TEAEs identified as application
site reactions
63 (33.9) 15 (8.2)
Most commonly reported TEAEs ($2 patients in either
treatment group)
Burning sensation* 26 (14.0) 4 (2.2)
Application site pain* 18 (9.7) 4 (2.2)
Pain in extremity* 17 (9.1) 8 (4.4)
Erythema 2 (1.1) 0 (.0)
TEAEs identified as application
site painy
60 (32.3) 14 (7.7)
TEAEs leading to permanent
discontinuation
0 (0) 1 (.5)
Hypertensionz 0 (0) 1 (.5)
Drug-related TEAEs (>2.0%
patients in either treatment
group)x
65 (34.9) 23 (12.6)
Drug-related TEAEs leading to
permanent discontinuationx
0 (0) 0 (0)
Severe TEAEs 4 (2.2) 8 (4.4)
Drug-related severe TEAEsx 3 (1.6) 0 (0)
Severe burning sensation 2 (1.1) 1 (.5)
Severe application site pain 1 (.5) 0 (0)
Serious TEAEs 2 (1.1) 7 (3.8)
Drug-related serious TEAEsx 0 (0) 0 (0)
Deaths 0 (0) 0 (0)
*Also TEAEs identified as application site pain.
yComprised of application site pain, pain in extremity, and burning sensation.
zNot considered drug-related.
xPossible or probable, as assessed by the investigator, or records for which rela-
tionship was missing.
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methodology in studies of PDPN makes comparison
of this study with previous studies of other pain-
relieving agents difficult. The optimal approach to
comparing the efficacy of 2 drug treatments is a
head-to-head comparison within the same study,
because only this approach is not beset by differences
in study design and conduct that affect the validity of
meta-analyses.20 Results from ELEVATE, a head-to-
head comparison of capsaicin 8% patch with pregaba-
lin in nondiabetic patients with PNP, showed that the
capsaicin 8% patch was noninferior to pregabalin in
pain relief. This head-to-head study also reported the
capsaicin 8% patch to be associated with a faster onset
of action, greater patient satisfaction with treatment,
and fewer systemic side effects,12 replicating the safety
profile seen in this and previous studies with the capsa-
icin 8% patch.
The median time to treatment response with the
capsaicin 8% patch in this study was 19 days, comparedwith 72 days with placebo patch. Although pain relief
was substantially faster with capsaicin 8% than pla-
cebo, it occurred approximately 1 week later than in
studies in PHN and HIV-DSPN.3,6,13,19 Although
further research is required to ascertain the reason
for this difference, there are several factors that may
help explain this observation. Physiological
characteristics of the skin of patients with PDPN, such
as thickened stratum corneum, waxy skin,15 and
reduced hydration state,18 may differ from that of pa-
tients with PHN and HIV-DSPN, potentially slowing the
absorption of capsaicin and delaying pain relief. In
addition, patients with PDPN may have reduced
numbers of vanilloid receptor subtype 1 receptors,
potentially creating a rate-limiting effect on the speed
of capsaicin 8% patch response.
An interesting finding in this study was the duration of
response after treatment with the placebo patch. In 2 pre-
vious double-blinded studies with the capsaicin 8% patch
versus active control (.04% capsaicin) in patients with
PHN, the response in the control group was maintained
for 12 weeks and this was thought to be due to the use
of active control that caused mild burning and erythema,
but had no effect on epidermal nerve fiber density.3,13
Although a placebo patch without capsaicin was used in
this study, the placebo response was also maintained for
12 weeks. This was an interesting finding from this study
and is in line with a recent analysis of placebo response
in PNP studies by the Initiative on Methods,
Measurement, and Pain Assessment in Clinical Trials
(IMMPACT), who reported that the likelihood of study
failure and magnitude of placebo response are greater in
studies in PDPN compared with PHN.9
Overall, more patients in the capsaicin 8%patch group
(33.9%) reported application site TEAEs compared with
the placebo group (8.2%). It is possible that application
site reactions may have led to functional unblinding of
patients in the capsaicin group and that this may have
influenced the results obtained from the study. Because
a ‘‘masking assessment’’ was not performed at the final
visit, the likelihood of such functional unblinding cannot
specifically be determined. The results of the study
should therefore be considered with this limitation in
mind. Another important limitation to consider with
this study is the treatment delta observed in the primary
analysis, which was narrow because of the substantial
placebo response observed. The placebo response was
not unexpected, because in this study patients in the
capsaicin and placebo groups were given a physical
patch application. However, the difference between
capsaicin 8% patch and placebo was within the bound-
ary of statistical significance in the primary analysis
(P = .025 for capsaicin vs placebo). Because of the small
effect size observed, relative to placebo, and in common
with other treatments for PDPN, clinicians will need to
consider the clinicalmeaningfulness on the basis of an in-
dividual patient’s needs and preferences. This important
issue of clinical meaningfulness should be evaluated in
all future studies of neuropathic pain. ‘Bedside’ sensory
testing was performed in this multicenter study because
it was not feasible to provide adequate training on the
Figure 8. (A) Proportion of patients who reported improved, remained the same, or worsened sensory or reflex function by EoS
(safety analysis set; SAS). (B) Change in proportion of patients reporting sensory and reflex testing categories from baseline to EoS
(SAS). (C) Change in proportion of patients reporting sensory and reflex testing categories from baseline to EoS (SAS). Abbreviations:
Cap, capsaicin 8% patch; Pla, placebo.
Simpson et al The Journal of Pain 11Quantitative Sensory Testing (QST) technique across all
centers, or standardize all assessments in all study cen-
ters, and undertaking the full array of QST techniques
imposes a significant time burden on clinicians. However,
potential advantages of QST are a quantification of sen-
sory deficits and allodynia/hyperalgesia, and standard-
ized values for several painful sites.4,14 Although not
feasible in this multicenter study, one cannot exclude
that QST would have been more sensitive to detect
small variations of thermal or mechanical deficits. The
overall study findings may be perceived as limited by
the duration of 12 weeks and assessment of a single
treatment with the capsaicin 8% patch. A separate
open-label study has therefore assessed the long-term
safety and tolerability (primary end point) and efficacy
of capsaicin 8% patch repeat treatment with standard
of care versus standard of care alone over 52weeks in pa-
tients with PDPN (NCT01478607).22Conclusions
This study showed that, in patients with PDPN, the
capsaicin 8% patch provided modest and statisticallysignificant improvements in pain relief and improved
sleep quality compared with a placebo patch, was
well tolerated, and was not associated with any sensory
deterioration or new safety concerns. The efficacy of
the capsaicin 8% patch is similar to that of other drug
treatments for neuropathic pain, but with a lack of sys-
temic AEs, and therefore should be considered for a
place in treatment.
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